首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   21057篇
  免费   1464篇
  国内免费   157篇
耳鼻咽喉   354篇
儿科学   353篇
妇产科学   409篇
基础医学   2807篇
口腔科学   511篇
临床医学   1899篇
内科学   4384篇
皮肤病学   590篇
神经病学   1350篇
特种医学   1135篇
外科学   2769篇
综合类   779篇
现状与发展   1篇
一般理论   14篇
预防医学   1088篇
眼科学   722篇
药学   1639篇
中国医学   171篇
肿瘤学   1703篇
  2023年   205篇
  2022年   433篇
  2021年   773篇
  2020年   442篇
  2019年   549篇
  2018年   705篇
  2017年   511篇
  2016年   623篇
  2015年   820篇
  2014年   1007篇
  2013年   1077篇
  2012年   1711篇
  2011年   1663篇
  2010年   933篇
  2009年   836篇
  2008年   1175篇
  2007年   1150篇
  2006年   1126篇
  2005年   1066篇
  2004年   843篇
  2003年   692篇
  2002年   567篇
  2001年   526篇
  2000年   511篇
  1999年   405篇
  1998年   132篇
  1997年   111篇
  1996年   76篇
  1995年   86篇
  1994年   82篇
  1993年   64篇
  1992年   155篇
  1991年   167篇
  1990年   137篇
  1989年   129篇
  1988年   116篇
  1987年   133篇
  1986年   106篇
  1985年   94篇
  1984年   73篇
  1983年   69篇
  1982年   36篇
  1979年   60篇
  1977年   39篇
  1975年   38篇
  1974年   39篇
  1973年   36篇
  1972年   37篇
  1970年   35篇
  1969年   40篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
The development of disease‐modifying therapies (DMT) in multiple sclerosis (MS) has rapidly evolved over the last few years and continues to do so. Prior to the United States Food and Drug Administration approval of the immunomodulatory agent, interferon‐β1b in 1993, no other drug had been shown to alter the course of the disease in a controlled study of MS. At present, there are five licenced disease‐modifying agents in MS – interferon‐β1b, interferon‐β1a, glatiramer acetate, natalizumab and mitoxantrone. All have shown significant therapeutic efficacy in large controlled trials. However, current therapies are only partially effective and are not free from adverse effects. Moreover, available DMTs are overwhelmingly biased in favour of those with relapsing‐remitting disease. Effective treatment for progressive MS is severely limited, with only interferon‐β1b and mitoxantrone having licenced use in secondary progressive, but not primary progressive disease. Monoclonal antibodies, such as natalizumab selectively target immune pathways involved in the pathogenic process of MS. Alemtuzumab, daclizumab and rituximab are other notable monoclonal antibodies currently undergoing phase II and III trials in MS. Alemtuzumab has so far shown promising therapeutic benefit in relapsing disease, although immunological adverse effects have been a problem. Oral therapies have the benefit of improved tolerability and patient compliance compared with current parenteral treatments. Cladribine and fingolimod (FTY720) have shown encouraging results in their phase III clinical trials. It is also worth noting the evidence for starting DMT in patients with clinically isolated syndrome, whereby early treatment has shown to delay the onset of clinically definite MS in separate phase III studies.  相似文献   
994.
995.
996.
We report a rare case of giant mesenteric lipoma presenting with colicky abdominal pain. A 29-yr-old woman underwent laparoscopic resection for a giant mesenteric lipoma causing compression of the ileal loop. The resected ileal segment was encased by a giant fatty tissue, and normal mucosal fold patterns of the resected ileum were effaced by the mass. Microscopically, the mass was characterized by homogenous mature adipose tissue without cellular atypia, which was compatible with the diagnosis of a mesenteric lipoma. Despite the benign nature of this tumor, total excision with or without the affected intestinal loop should be considered if intestinal symptoms such as abdominal pain are present.  相似文献   
997.
Glioma stem cells (GSCs) are known to be maintained within a “vascular niche” thereby, disruption of this microenvironment using antiangiogenesis agents is a promising therapeutic modality. However, this regimen leads to treatment failure and tumor recurrence in patients with glioblastoma multiforme (GBM). Therefore, more effective therapeutic approaches that can eradicate GSCs and the bulk tumors are needed. Toward this goal, we examined the antitumor effects of an antiangiogenesis approach combined with conventional chemotherapy on suppressing glioma xenograft growth. We established three genetically engineered mesenchymal stem cell (MSC) lines (GE-AF-MSCs) by stably transducing the gene encoding endostatin (an antiangiogenesis factor), the gene encoding secretable form of carboxylesterase 2 (sCE2, a prodrug-activating enzyme), or a mixture of both genes. Among the three GE-AF-MSC cell lines, injection of amniotic fluid (AF)-MSCs-endostatin-sCE2 cells into U87MG-EGFRvIII-driven orthotopic brain tumor and postsurgery tumor recurrence models, and subsequent CPT11 treatment yielded the strongest antitumor responses, including diminished angiogenesis, increased cell death, and a reduced Nestin-positive GSC population. Therefore, our antitumor strategy provides a novel basis for designing stem cell-mediated therapeutic approaches to target and eradicate GSCs and the bulk tumors.  相似文献   
998.
Caesalpinia sappan (C. sappan) is a medicinal plant used for promoting blood circulation and removing stasis. During a screening procedure on medicinal plants, the ethylacetate extract of the lignum of C. sappan (CLE) showed inhibitory activity on arginase which has recently been reported as a novel therapeutic target for the treatment of cardiovascular diseases such as atherosclerosis. CLE inhibited arginase II activity prepared from kidney lysate in a dose-dependent manner. In HUVECs, inhibition of arginase activity by CLE reciprocally increased NOx production through enhancement of eNOS dimer stability without any significant changes in the protein levels of eNOS and arginase II expression. Furthermore, CLE-dependent arginase inhibition resulted in increase of NO generation and decrease of superoxide production on endothelium of isolated mice aorta. These results indicate that CLE augments NO production on endothelium through inhibition of arginase activity, and may imply their usefulness for the treatment of cardiovascular diseases associated with endothelial dysfunction.  相似文献   
999.
1000.

Purpose  

To determine the accuracy of multi-detector CT (MDCT) compared with the surgical findings, such as peritoneal seeding and metastatic lymph nodes, in ovarian cancer patients.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号